Table 1.

Studies comparing different durations of dual antiplatelet therapy after PCI

Study (year)	Randomisation	Sample size	Primary endpoint	Design and randomisation	% ACS	Proportion with Newer-Generation DES (%)	Primary endpoint (short vs. long DAPT)
RESET (2012) [13]	3 vs. 12 months DAPT	2,117	Cardiac death, MI, ST, revasc. or bleeding	Non-inferiority Randomisation at time of PCI	55	85	4.7% in both arms (pNI <0.001)
OPTIMIZE (2014) [14]	3 vs. 12 months DAPT	3,119	NACCE—death, MI, stroke, or bleed	Non-inferiority Randomisation at time of PCI	32	100	6.0% with 3 months DAPT vs. 5.8% with 1‑year DAPT (pNI = 0.002)
EXCELLENT (2011) [15]	6 vs. 12 months DAPT	1,443	Cardiac Death, MI, or ischemia driven TVR	Non-inferiority Randomisation at time of PCI	51	75	4.8% with 6‑months vs. 4.3% with 1‑year DAPT (pNI = 0.001)
ISAR-SAFE (2014) [16]	6 vs. 12 months DAPT	4,000* (planned: 6,000)	Death, MI, stroke, or TIMI major bleed	Non-inferiority Randomisation at DAPT discontinuation	40	72	1.5% with 6 months DAPT vs. 1.6% with 1‑year DAPT (pNI < 0.001)
SECURITY (2014) [17]	6 vs. 12 months DAPT	1,399* (planned: 2,740)	Cardiac death, MI, ST, or stroke	Non-inferiority Randomisation at time of PCI	38	100	4.5% with 6‑months DAPT vs. 5.7% with 1‑year DAPT (pNI ≤ 0.05)
PRODIGY (2012) [20]	6 vs. 24 months DAPT	1,970	Death, MI, stroke	Superiority Randomisation 1 month after PCI	75	50	10.0% with 6 months DAPT vs. 10.1% with 2‑year DAPT (p = 0.91)
ITALIC (2014) [21]	6 vs. 24 months DAPT	1,822* (planned: 2,475)	Death, MI, urgent TVR, stroke or bleeding	Non-inferiority Randomisation at time of PCI	24	100	1.6% with 6 months DAPT vs. 1.5% with 2‑year DAPT
ARCTIC Interruption (2014) [22]	12 vs. 18–24 months	1,259	Death/MI/ST/CVA/TVR	Superiority Randomisation at DAPT discontinuation	26	63	4.0% in both arms (median 17 months FU) (p = 0.58)
DAPT (2015) [23]	12 vs. 30 months	9,961	1 ST 2 MACE	Superiority Randomisation at DAPT discontinuation	43	59	ST: 1.4% vs. 0.4% and MACE 4.1 vs. 2.1% (p < 0.001)
DES-LATE (2010) [24]	12 vs. 36 months	5,045	Cardiac death/MI/ CVA	Superiority Randomisation at DAPT discontinuation	61	30	2.4% SAPT vs. 2.7% DAPT (p = 0.75)
OPTIDUAL (2015) [25]	12 vs. 48 months	1,385* (planned: 1,966)	Death/MI/ CVA/bleeding	Superiority Randomisation at DAPT discontinuation	36	59	7.5% SAPT vs. 5.8% DAPT (p = 0.17)

^* Inclusion of patients terminated prematurely

RESET REal Safety and Efficacy of 3‑month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation, NI non-inferior, OPTIMIZE Optimized Duration of Clopidogrel Therapy Following Treatment With the Zotarolimus-Eluting Stent in Real-World Clinical Practice, EXCELLENT Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting, ISAR-SAFE Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting, SECURITY Second-Generation Drug-Eluting Stent Implantation Followed By Six- Versus Twelve-Month Dual Antiplatelet Therapy, PRODIGY Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study, ITALIC Is There a Life for DES After Discontinuation of Clopidogrel, ARCTIC Assessment with a double Randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and Clopidogrel after DES implantation, and (2) Treatment Interruption versus Continuation, 1 year after stenting, DAPT Dual AntiPlatelet Therapy, DES-LATE Optimal Duration of Clopidogrel Therapy With DES to Reduce Late Coronary Arterial Thrombotic Event, OPTIDUAL OPTImal DUAL antiplatelet therapy, CVA cerebrovascular accident, DAPT dual antiplatelet therapy, DES drug-eluting stent, MACE major adverse cardiac event, MI myocardial infarction, NACCE Net Adverse clinical and cerebral event, PCI percutaneous coronary intervention, SAPT single antiplatelet therapy, ST stent thrombosis. TVR target vessel revascularisation